Review



grp75  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Novus Biologicals grp75
    Grp75, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/grp75/product/Novus Biologicals
    Average 92 stars, based on 3 article reviews
    grp75 - by Bioz Stars, 2026-02
    92/100 stars

    Images



    Similar Products

    92
    Novus Biologicals grp75
    Grp75, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/grp75/product/Novus Biologicals
    Average 92 stars, based on 1 article reviews
    grp75 - by Bioz Stars, 2026-02
    92/100 stars
      Buy from Supplier

    93
    Novus Biologicals recombinant mortalin
    Blind SELEX to identify potential biomarkers on pancreatic cancer. (A) The schematic workflow of blind SELEX is depicted. After untargeted SELEX to identify differently expressed markers on plasma membrane of PANC-1 cells, aptamers are enriched in vitro . Target ligands were retrieved via affinity pull-down assays using biotinylated aptamers. After affinity pull-down assays, MS/MS is used to achieve peptide fingerprinting. Finally, the binding of aptamer with the target ligand is validated by surface plasmon resonance. (B) Competition assay was performed to determine whether P19 and P1 bind to the same epitope. The fluorescence intensity was quantified using confocal microscopy. *One-way ANOVA test; * P ≤ .05, ** P ≤ .01. (C) Ten percent of polyacrylamide gel electrophoresis was used to separate immobilized protein samples after pull-down with biotinylated P19, P1, and negative control RNAs. Coomassie-stained gels: M (marker), P19 (lane 1), P1 (lane 2), and NC (irrelevant RNA, lane 3). Arrow indicates target antigens. (D) MS/MS spectra of aptamer binding ligand. Peptide matching and MS/MS spectra of P19 (left) and P1 (right) affinity-purified peptides. Inset: amino acid sequence of the parent peptide showing b- and y-ion series coverage. Target epitopes are highlighted in yellow. (E) Biosensor analysis of the <t>mortalin-aptamer</t> interaction. Binding of mortalin to the P19 (left) and P1 (right) was shown. Biotinylated P19 or P1 was bound to a streptavidin-coupled carboxyl methyl dextran surface, and binding was measured using the SPR technique. The increased response unit was shown in a dose-dependent manner.
    Recombinant Mortalin, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant mortalin/product/Novus Biologicals
    Average 93 stars, based on 1 article reviews
    recombinant mortalin - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    90
    Enzo Biochem recombinant human grp75/mortalin/mthsp70
    Blind SELEX to identify potential biomarkers on pancreatic cancer. (A) The schematic workflow of blind SELEX is depicted. After untargeted SELEX to identify differently expressed markers on plasma membrane of PANC-1 cells, aptamers are enriched in vitro . Target ligands were retrieved via affinity pull-down assays using biotinylated aptamers. After affinity pull-down assays, MS/MS is used to achieve peptide fingerprinting. Finally, the binding of aptamer with the target ligand is validated by surface plasmon resonance. (B) Competition assay was performed to determine whether P19 and P1 bind to the same epitope. The fluorescence intensity was quantified using confocal microscopy. *One-way ANOVA test; * P ≤ .05, ** P ≤ .01. (C) Ten percent of polyacrylamide gel electrophoresis was used to separate immobilized protein samples after pull-down with biotinylated P19, P1, and negative control RNAs. Coomassie-stained gels: M (marker), P19 (lane 1), P1 (lane 2), and NC (irrelevant RNA, lane 3). Arrow indicates target antigens. (D) MS/MS spectra of aptamer binding ligand. Peptide matching and MS/MS spectra of P19 (left) and P1 (right) affinity-purified peptides. Inset: amino acid sequence of the parent peptide showing b- and y-ion series coverage. Target epitopes are highlighted in yellow. (E) Biosensor analysis of the <t>mortalin-aptamer</t> interaction. Binding of mortalin to the P19 (left) and P1 (right) was shown. Biotinylated P19 or P1 was bound to a streptavidin-coupled carboxyl methyl dextran surface, and binding was measured using the SPR technique. The increased response unit was shown in a dose-dependent manner.
    Recombinant Human Grp75/Mortalin/Mthsp70, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human grp75/mortalin/mthsp70/product/Enzo Biochem
    Average 90 stars, based on 1 article reviews
    recombinant human grp75/mortalin/mthsp70 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    Image Search Results


    Blind SELEX to identify potential biomarkers on pancreatic cancer. (A) The schematic workflow of blind SELEX is depicted. After untargeted SELEX to identify differently expressed markers on plasma membrane of PANC-1 cells, aptamers are enriched in vitro . Target ligands were retrieved via affinity pull-down assays using biotinylated aptamers. After affinity pull-down assays, MS/MS is used to achieve peptide fingerprinting. Finally, the binding of aptamer with the target ligand is validated by surface plasmon resonance. (B) Competition assay was performed to determine whether P19 and P1 bind to the same epitope. The fluorescence intensity was quantified using confocal microscopy. *One-way ANOVA test; * P ≤ .05, ** P ≤ .01. (C) Ten percent of polyacrylamide gel electrophoresis was used to separate immobilized protein samples after pull-down with biotinylated P19, P1, and negative control RNAs. Coomassie-stained gels: M (marker), P19 (lane 1), P1 (lane 2), and NC (irrelevant RNA, lane 3). Arrow indicates target antigens. (D) MS/MS spectra of aptamer binding ligand. Peptide matching and MS/MS spectra of P19 (left) and P1 (right) affinity-purified peptides. Inset: amino acid sequence of the parent peptide showing b- and y-ion series coverage. Target epitopes are highlighted in yellow. (E) Biosensor analysis of the mortalin-aptamer interaction. Binding of mortalin to the P19 (left) and P1 (right) was shown. Biotinylated P19 or P1 was bound to a streptavidin-coupled carboxyl methyl dextran surface, and binding was measured using the SPR technique. The increased response unit was shown in a dose-dependent manner.

    Journal: Translational Oncology

    Article Title: Uncovering Differently Expressed Markers and Heterogeneity on Human Pancreatic Cancer

    doi: 10.1016/j.tranon.2020.100749

    Figure Lengend Snippet: Blind SELEX to identify potential biomarkers on pancreatic cancer. (A) The schematic workflow of blind SELEX is depicted. After untargeted SELEX to identify differently expressed markers on plasma membrane of PANC-1 cells, aptamers are enriched in vitro . Target ligands were retrieved via affinity pull-down assays using biotinylated aptamers. After affinity pull-down assays, MS/MS is used to achieve peptide fingerprinting. Finally, the binding of aptamer with the target ligand is validated by surface plasmon resonance. (B) Competition assay was performed to determine whether P19 and P1 bind to the same epitope. The fluorescence intensity was quantified using confocal microscopy. *One-way ANOVA test; * P ≤ .05, ** P ≤ .01. (C) Ten percent of polyacrylamide gel electrophoresis was used to separate immobilized protein samples after pull-down with biotinylated P19, P1, and negative control RNAs. Coomassie-stained gels: M (marker), P19 (lane 1), P1 (lane 2), and NC (irrelevant RNA, lane 3). Arrow indicates target antigens. (D) MS/MS spectra of aptamer binding ligand. Peptide matching and MS/MS spectra of P19 (left) and P1 (right) affinity-purified peptides. Inset: amino acid sequence of the parent peptide showing b- and y-ion series coverage. Target epitopes are highlighted in yellow. (E) Biosensor analysis of the mortalin-aptamer interaction. Binding of mortalin to the P19 (left) and P1 (right) was shown. Biotinylated P19 or P1 was bound to a streptavidin-coupled carboxyl methyl dextran surface, and binding was measured using the SPR technique. The increased response unit was shown in a dose-dependent manner.

    Article Snippet: Recombinant mortalin was purchased from Novus Biologicals (NBC1-18380).

    Techniques: Clinical Proteomics, Membrane, In Vitro, Tandem Mass Spectroscopy, Binding Assay, SPR Assay, Competitive Binding Assay, Fluorescence, Confocal Microscopy, Polyacrylamide Gel Electrophoresis, Negative Control, Staining, Marker, Affinity Purification, Sequencing